William Richard White is Chief Financial Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 41,152 shares of AKRO, which is worth approximately $1.26 Million. The most recent transaction as insider was on Dec 27, 2022, when has been sold 19,001 shares (Common Stock) at a price of $7.01 per share, resulting in proceeds of $133,197. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 41.2K
1.53% 3M change
122.83% 12M change
Total Value Held $1.26 Million

William Richard White Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 27 2022
BUY
Exercise of conversion of derivative security
$133,197 $7.01 p/Share
19,001 Added 30.83%
42,625 Common Stock
Dec 09 2022
BUY
Grant, award, or other acquisition
-
19,195 Added 44.83%
23,624 Common Stock
Oct 13 2022
SELL
Open market or private sale
$796,400 $39.82 p/Share
20,000 Reduced 81.87%
4,429 Common Stock
Oct 13 2022
BUY
Exercise of conversion of derivative security
$140,200 $7.01 p/Share
20,000 Added 45.02%
24,429 Common Stock
Sep 13 2022
SELL
Open market or private sale
$882,375 $27.15 p/Share
32,500 Reduced 88.01%
4,429 Common Stock
Sep 13 2022
BUY
Exercise of conversion of derivative security
$227,825 $7.01 p/Share
32,500 Added 46.81%
36,929 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$9,251 $8.03 p/Share
1,152 Added 20.64%
4,429 Common Stock
Jan 14 2022
SELL
Open market or private sale
$213,691 $22.03 p/Share
9,700 Reduced 74.75%
3,277 Common Stock
Jan 14 2022
BUY
Exercise of conversion of derivative security
$67,997 $7.01 p/Share
9,700 Added 42.77%
12,977 Common Stock
Dec 21 2021
SELL
Open market or private sale
$2,200 $22.0 p/Share
100 Reduced 2.96%
3,277 Common Stock
Dec 21 2021
BUY
Exercise of conversion of derivative security
$701 $7.01 p/Share
100 Added 2.88%
3,377 Common Stock
Dec 17 2021
SELL
Open market or private sale
$70,528 $22.04 p/Share
3,200 Reduced 49.41%
3,277 Common Stock
Dec 17 2021
BUY
Exercise of conversion of derivative security
$22,432 $7.01 p/Share
3,200 Added 33.07%
6,477 Common Stock
Nov 01 2021
SELL
Open market or private sale
$144,560 $22.24 p/Share
6,500 Reduced 66.48%
3,277 Common Stock
Nov 01 2021
BUY
Exercise of conversion of derivative security
$45,565 $7.01 p/Share
6,500 Added 39.93%
9,777 Common Stock
Oct 01 2021
SELL
Open market or private sale
$143,390 $22.06 p/Share
6,500 Reduced 66.48%
3,277 Common Stock
Oct 01 2021
BUY
Exercise of conversion of derivative security
$45,565 $7.01 p/Share
6,500 Added 39.93%
9,777 Common Stock
Sep 01 2021
SELL
Open market or private sale
$205,416 $24.0 p/Share
8,559 Reduced 72.31%
3,277 Common Stock
Sep 01 2021
BUY
Exercise of conversion of derivative security
$59,999 $7.01 p/Share
8,559 Added 41.97%
11,836 Common Stock
Aug 02 2021
SELL
Open market or private sale
$97,835 $22.03 p/Share
4,441 Reduced 57.54%
3,277 Common Stock
Aug 02 2021
BUY
Exercise of conversion of derivative security
$31,131 $7.01 p/Share
4,441 Added 36.52%
7,718 Common Stock
Jul 06 2021
SELL
Open market or private sale
$159,380 $24.52 p/Share
6,500 Reduced 66.48%
3,277 Common Stock
Jul 06 2021
BUY
Exercise of conversion of derivative security
$45,565 $7.01 p/Share
6,500 Added 39.93%
9,777 Common Stock
May 03 2021
SELL
Open market or private sale
$128,352 $30.56 p/Share
4,200 Reduced 64.91%
2,270 Common Stock
May 03 2021
BUY
Exercise of conversion of derivative security
$29,442 $7.01 p/Share
4,200 Added 39.36%
6,470 Common Stock

Also insider at

VTYX
Ventyx Biosciences, Inc. Healthcare
GMTX
Gemini Therapeutics, Inc. Healthcare
WRW

William Richard White

Chief Financial Officer
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO